Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Intercept Pharma (ICPT – Research Report) and ...

Sarepta Therapeutics (SRPT) is under Wall Street’s microscope right now.Shares dropped by 49% in a single session last week, following the release of disappointing clinical trial results ...

Detailed price information for Zimmer Biomet Holdings (ZBH-N) from The Globe and Mail including charting and trades.

Detailed price information for Alpha Teknova Inc (TKNO-Q) from The Globe and Mail including charting and trades.

14 analysts have expressed a variety of opinions on Sarepta Therapeutics (NASDAQ: ... Analyst Expectations For Sarepta Therapeutics's Future November 25, 2024 — 08:01 am EST.

Explore Sarepta Therapeutics analyst ratings and price targets (NASDAQ:SRPT) on Benzinga. Stay updated on expert opinions and forecasts for SRPT stock.

Sarepta reports a second fatal case of acute liver failure linked to Elevidys. Analyst cuts Sarepta’s rating due to uncertain safety and future revenue potential. A new wave of value and ...

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions.

is the subject of a research note from Lazard Capital Markets Wednesday in which analyst Bill Tanner summarizes feedback from some doctors in the Duchenne muscular ...

Sarepta Therapeutics Inc. shares lost more than half their value in after-hours trading Thursday, after the company said a drug candidate produced mixed results in a clinical study.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report), AlloVir (ALVR – Research Report) and Bristol-Myers Squibb (BMY ...

Sarepta Therapeutics (SRPT) is under Wall Street’s microscope right now.Shares dropped by 49% in a single session last week, following the release of disappointing clinical trial results ...